Outlook Therapeutics, Inc.

OTLK

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001649989

SEC filings (opens in a new tab)

Insider trades, last 90 days

4 buys · 0 sells

Bought $2.6M
Open-market purchases (P) and sales (S), counted by Form 4 filing.

View insider trades

13F holders, Q2 2026

68

+13 vs. Q1 2026
Total value $32.52M

View 13F holders

Superinvestors holding OTLK

0

None of the superinvestors held OTLK at the end of Q2 2026.

See all holders

Price chart

Chart by TradingView (opens in a new tab)

Latest insider trades

Open-market purchases and sales by OTLK insiders, newest first.

Insider trades
Filed (ET)	Trade date	Insider	Transaction	Shares	Avg price	Value	Shares after	Holding change	Filing
Aug 14, 20268:57 PM ET	Aug 14, 2026	Jahr Robert CharlesChief Executive Officer	PPurchaseCommon Stock	+151.52K	–	–	151.52K	New position	SEC
Aug 14, 20268:57 PM ET	Aug 14, 2026	Jahr Robert CharlesChief Executive Officer	PPurchaseCommon Stock · Derivative	+151.52K	–	–	151.52K	–	SEC
Aug 14, 20267:52 PM ET	Aug 12, 2026	Sukhtian Ghiath M. and 1 otherDirector, 10% Owner	PPurchaseCommon Stock	+2.53M	$0.99	+$2.5M	24.62M	+11.4%	SEC
Aug 14, 20267:52 PM ET	Aug 12, 2026	Sukhtian Ghiath M. and 1 otherDirector, 10% Owner	PPurchaseCommon Stock · Derivative	+2.53M	$0.00	$0	2.53M	–	SEC
Aug 14, 20267:39 PM ET	Aug 14, 2026	KENYON LAWRENCE AChief Financial Officer	PPurchaseCommon Stock	+101.01K	–	–	106.96K	+1,698.8%	SEC

Top 5 13F holders, Q2 2026

The largest institutional positions in OTLK at the end of Q2 2026.

Institutions holding OTLK in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
VANGUARD CAPITAL MANAGEMENT LLC	4,376,872	$6.96M	0.00%	+2,409,712+122.5%	Added
PERCEPTIVE ADVISORS LLC	3,139,216	$4.99M	0.08%	+3,139,216	New
MARSHALL WACE, LLP	1,987,578	$3.16M	0.00%	+1,987,578	New
BlackRock, Inc.	1,668,579	$2.65M	0.00%	+1,191,108+249.5%	Added
JANE STREET GROUP, LLC	1,425,270	$2.27M	0.00%	+1,425,270	New